Maximizing Current Therapies and Exploring Future Directions as PARP Inhibitors Take the Stage in Prostate Cancer

Released On
April 5, 2021

Expires On
April 5, 2022

Media Type

Completion Time
120 minutes

Genetics, Hematology-Oncology, Pathology, Urology

Prostate Cancer, Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is sponsored by the Academy for Continued Healthcare Learning, in partnership with The University of Texas MD Anderson Cancer Center.


This activity is supported by an educational grant from Pfizer.


Credit Available

  • Physicians — maximum of 2.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for medical oncologists, urologists, pathologists, nurse practitioners, physician assistants and APNs who care for patients with prostate cancer.

Program Overview

This curriculum features expert commentaries and case discussions that synthesize data around PARP inhibition and its evolving place in the treatment of patients with prostate cancer. Faculty provide practical guidance to apply available and emerging data in real-world decision-making that clinicians are faced with on a daily basis including: interpreting results to inform treatment decisions, biomarker testing, patient selection, and combination therapy. Video modules are also available as downloadable audio podcasts and transcripts.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Outline the scientific rationale and the mechanisms of action of PARP inhibitors (PARPi) for advanced prostate cancer
  • Interpret recent PARPi clinical trial findings and the practice-changing impact for optimizing prostate cancer management
  • Review the importance of genomic testing to identify patients who will benefit from treatment strategies incorporating PARPi for advanced prostate cancer
  • Apply the most recent clinical data on PARPi to inform clinical decision-making and personalize management of advanced prostate cancer


Neeraj Agarwal, MD

Professor of Medicine
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, UT

Celestia Higano, MD, FACP

Adjunct Professor, Department of Urologic Science
University of British Columbia
Medical Director, Prostate Cancer Supportive Care Program Vancouver Prostate Centre
Vancouver, BC

Daniel Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Co-Director, Signal Transduction Research Program Yale School of Medicine, Yale Cancer Center
New Haven, CT

Patrick G. Pilié, MD

Assistant Professor
GU Medical Oncology
MD Anderson Cancer Center
Houston, TX

Neal Shore, MD, FACS

Medical Director, Carolina Urologic Research Center
Urologist, Atlantic Urology Clinics
Myrtle Beach, SC

Accreditation Statement & Credit Designation

Physician Continuing Medical Education

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.


Disclosures of Conflicts of Interest

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Neeraj Agarwal, MD

  • Consultant (Occasional): Astellas, Foundation Medicine, Merck
  • Consultant (Retained): Astellas, AstraZeneca, Bristol Myers Squibb, Bayer, Clovis, EMD Serono, Eisai, Eli Lilly, Exelixis, Foundation Medicine, Genentech, Janssen, Nektar, Novartis, Pfizer, Pharmacyclics, Seattle Genetics
  • Grant/Research Support Recipient: AstraZeneca, Bristol Myers Squibb, Bavarian Nordic, Bayer, Calithera, Celldex, Clovis, EMD Serono, Eisai, Eli Lilly, Exelixis, Genentech, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, Tracon

Celestia Higano, MD, FACP

  • Consultant (Occasional): Astellas, AstraZeneca, Bayer, Ferring, Genentech, Janssen, Menarini, Myovant, Tolamr
  • Consultant (Retained): CTI Biopharma
  • Independent Data Monitoring Committee: Advantagene, Alliance Foundation Trials, ExelixisInstitutional Clinical Research Funding: Hoffman-Laroche, Pfizer, Emergent, Genentech, eFFECTOR Therapeutics, Aptevo, Astellas, AstraZeneca, Clovis, Dendreon

Daniel Petrylak, MD

  • Consultant (Occasional): Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Incyte, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Seattle Genetics, Urogen
  • Grant/Research Support Recipient: : Ada Cap (Advanced Accelerator Applications), Agensys Inc., Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics
  • Stock Shareholder (excluding mutual funds): Bellicum

Patrick G. Pilié, MD, has nothing to disclose

Neal Shore, MD, FACS

  • Consultant (Occasional): Abbvie, Ambry, Amgen, BMS, Boston Scientific, Clovis Oncology, Fergene, Ferring, Foundation Medicine, Janssen, MDX Health, Merck, Myovant, Myriad, Nymox, Pfizer, PlatformQ, Sanofi, Tolmar, Astellas, AstraZeneca, Bayer, Dendreon, Exact Imaging, Invitae
  • Speaker Bureau: Clovis Oncology, Janssen, Pfizer, Astellas, Bayer

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Talazoparib and emerging combination regimens.

Instructions for Participation and Credit

To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 70% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Contact Information

For questions, contact Laurie Novoryta at